Avadomide promoted T-cell proliferation and chemokine synthesis, upregulated PD-L1 in the immune tumor microenvironment, and stimulated activation of cytotoxic CD8+ T cells when combined with anti-PD-L1 antibodies in patient-derived xenograft tumors. Here, CD8A is linked to neoplasm.